Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis and hepatocellular carcinoma. HCV NS5A, one of non-structural proteins of HCV, was suggested to play a role in oncogenic transformation. Since the tumor suppressor p53 is important for preventing neoplastic transformation, we investigated the functional effects of HCV NS5A on p53. In vitro and in vivo coimmunoprecipitation and confocal microscopy were used to determine the interaction of NS5A and p53. HCV NS5A binds directly to p53 and colocalizes p53 in the perinuclear region. NS5A inhibits transcriptional transactivation by p53 in a dose-dependent manner by use of a reporter assay. Down regulation of endogenous p21/waf1 expression, which is activated by p53 in Hep3B cells, by NS5A was demonstrated by using FLAG-and FLAG-NS5A Hep3B stable cell lines. The effect of NS5A on p53-mediated apoptosis was determined by flow cytometry in both NS5A permanently and transiently transfected Hep3B cells with exogenous p53. The p53-induced apoptosis was abrogated by NS5A and the inhibition effect correlates well with the binding ability of NS5A to p53. In addition, HCV NS5A protein interacts with and colocalizes hTAF II 32, a component of TFIID and an essential coactivator of p53, in vivo. These results suggest that HCV NS5A interacts with and partially sequestrates p53 and hTAF II 32 in the cytoplasm and suppresses p53-mediated transcriptional transactivation and apoptosis during HCV infection, which may contribute to the hepatocarcinogenesis of HCV infection.
Introduction
Hepatitis C virus (HCV), a positive-stranded RNA virus of the Flaviviridae family (Houghton, 1996) , is recognized as a major causative agent of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Kuo et al., 1989; Saito et al., 1990; Shiratori et al., 1995) . The HCV genome is approximately 9.5 kb in length and encodes a large polyprotein precursor of about 3000 amino acids (aa) that is processed by a combination of host and viral proteases into at least 10 individual proteins: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B (Choo et al., 1991; Hijikata et al., 1991; Grakoui et al., 1993) .
The NS5A gene of HCV encodes a 447 aa phosphoprotein (aa 1973 to 2419 of the prototype HCV type 1b, HCV-J (Kato et al., 1990) ), which has differently phosphorylated forms of 56 and 58 kDa with modified serine residues (Kaneko et al., 1994 ). NS5A appears to play an important role in regulating HCV replication, although its precise function remains largely unclear. In transfected cells, HCV NS5A has been localized to the cytoplasmic membrane surrounding the nucleus (Ide et al., 1996; Moradpour et al., 1998; Polyak et al., 1999) . However, NS5A has a functional nuclear localization signal (NLS) sequence (PPRKKRTVV, between amino acids 2326 and 2334) (Ide et al., 1996) . Recently, a report showed a small amount of NS5A protein staining in the nucleus in a hepatoma cell line transfected with subgenomic HCV type 1b RNA (Lohmann et al., 1999) . In addition, caspase-like protease(s) cleaved NS5A, composed of amino acid residues 155 to 389, was localized in the nucleus in NS5A transiently expressing cells (Satoh et al., 2000) . Moreover, cells expressing NS5A exhibited a transformed phenotype and tumor formation in vivo Ghosh et al., 1999) . Several studies, including our own, showed that N-terminus-deleted NS5A has a transcriptional activation function (Chung et al., 1997; Kato et al., 1997; Tanimoto et al., 1997; Fukuma et al., 1998) . These results suggest that HCV NS5A may act as a transcriptional activator and could play a role in hepatocarcinogenesis.
The tumor suppressor p53 protein is involved in the maintenance of genomic integrity (Lane, 1992) , while activated p53 functions via its ability to transactivate gene expression and mediates its downstream events mainly by two major pathways: cell cycle arrest and apoptosis (Levine, 1997) . p53 is a potent inducer of apoptosis (Clarke et al., 1993; Lowe et al., 1993a,b) , which contributes its function to suppress oncogenic transformation (Eliyahu et al., 1989; Finlay et al., 1989) . Inhibition of its ability to regulate transcription by mutations or by association with viral oncoproteins correlates with oncogenesis Levine, 1993) . Most of the p53-interacting viral proteins were reported to suppress p53 function (Scheffner et al., 1992; Wang et al., 1994 Wang et al., , 1995 Dobner et al., 1996; Uchida et al., 1996; Elmore et al., 1997; Mulloy et al., 1998; Pise-Masison et al., 1998; Prost et al., 1998; Ray et al., 1997; Sheppard et al., 1999) . Among them, SV40 T antigen, adenovirus E1B 55-kDa, and HBx from HBV have been shown to inhibit p53-dependent apoptosis. Inhibition of p53-mediated apoptosis by these viral oncoproteins may play an important role in carcinogenesis. Since wild-type p53 had to be present in the cell nucleus in order to exert its function (Shaulsky et al., 1991) , it appears likely that sequestration of p53 in the cytoplasm may interfere with p53-mediated apoptosis, for which a high level of nuclear p53 is needed . Previous studies showed that HBx complexes with p53 in cytoplasm, partially preventing its nuclear entry and ability to induce apoptosis, which may contribute to the early stage of hepatocellular carcinogenesis (Elmore et al., 1997) .
In this study, we present data consistent with a role of HCV NS5A in the repression of p53 response element-directed transactivation of cellular genes and p21/waf1, a main downstream protein of the p53-dependent pathway. Co-immunoprecipitation and confocal experiments were used to show that HCV NS5A, via its C-terminal domain, binds to and partially sequesters p53 and hTAF II 32 in the cytoplasm, resulting in the abrogation of p53-mediated function.
Results

Interaction of HCV NS5A and p53
The ability of NS5A to interact with p53 was examined using an in vivo co-immunoprecipitation assay. The pCXN2-FLAG vector or NS5A expressing plasmids (pCXN2-FLAG-NS5A, pCXN2-FLAG-NS5A-N, pCXN2-FLAG-NS5A-C) were transiently cotransfected with p53 expressing plasmid (pCXN2-p53) into COS-7 cells. Cell lysates were immunoprecipitated (IP) with anti-FLAG M2 resin, and then analysed by immunoblotting (IB) using anti-p53 antibody (FL-393). Full length (aa 1973 to 2419 of HCV) and C-terminus (aa 2135 to 2419) of NS5A interact with p53, whereas N-terminus of NS5A (aa 1973 to 2331) does not bind to p53 (Figure 1b) . Equal expressing of full length, N-terminus, and C-terminus of FLAG-NS5A was also confirmed (second panel of Figure 1b ). These results suggest that the extreme Cterminus of NS5A (aa 2331 to 2419) may play an important role in NS5A binding to p53.
To rule out the possibility that NS5A interacts with p53 through SV40 large T antigen which is constitutively expressed in COS-7 cells, co-immunoprecipitation experiments were performed in Hep3B cells transiently transfected with p53-and FLAG-or FLAG-NS5A-expressing plasmids. p53 was specifically immunoprecipitated by FLAG M2 resin in Hep3B cells Figure 1 An analysis on the interaction between HCV NS5A and p53. (a) Construction of FLAG-NS5A expression plasmids. (b) The pCXN2-FLAG vector or NS5A expressing plasmids (pCXN2-FLAG-NS5A, pCXN2-FLAG-NS5A-N, pCXN2-FLAG-NS5A-C) were transiently cotransfected with p53 expressing plasmid (pCXN2-p53) into COS-7 cells. Cell lysates were immunoprecipitated (IP) with anti-FLAG M2 resin, and then analysed by immunoblotting (IB) using anti-p53 antibody . An arrow shows the coprecipitated p53. Equal expression of full length, N-terminus, and C-terminus of FLAG-NS5A was also confirmed. (c) Hep3B cells were transfected with 1 mg of pCXN2-p53 or pCXN2 vector and pCXN2-FLAG or pCXN2-FLAG-NS5A plasmids. Forty-eight hours after the transfection, cell lysates were immunoprecipitated with anti-FLAG M2 resin, and then analysed by immunoblotting using anti-p53 antibody. p53 was specifically immunoprecipitated in Hep3B cells co-transfected with FLAG-NS5A and p53 but not in those co-transfected with FLAG and p53 or transfected with FLAG-NS5A alone. (d) Interaction of HCV NS5A protein with p53 in the GST fusion protein binding assay. In vitro translated, 35 S-Met-labeled HCV p53 protein was mixed with GST or GST-NS5A fusion protein bound to glutathione-Sepharose 4B beads. Bound proteins were then analysed by SDS -PAGE followed by autoradiography.
35
S-Met-labeled p53 proteins bound to GST-NS5A protein but not control GST protein. An equal amount of GST and GST-NS5A fusion proteins were used in each experiment co-transfected with FLAG-NS5A and p53 but not in those co-transfected with FLAG and p53 or transfected with FLAG-NS5A alone (Figure 1c) . These results suggested that interaction of HCV NS5A and p53 is independent of the cell type used.
HCV NS5A protein binds p53 in vitro
To confirm the binding between HCV NS5A protein and p53, the in vitro translated, 35 S-Met-labeled p53 protein was incubated with an equal amount of GST or GST-NS5A fusion protein immobilized onto GST-sepharose beads. The bound protein was detected by SDS -PAGE followed by autoradiography. As shown in Figure 1d , the p53 protein bound to GST-NS5A but not to GST, indicating that the HCV NS5A binds to p53 directly.
Colocalization of HCV NS5A and p53 in Hep3B cells by immunofluorescent staining
An overexpression of p53 into Hep3B hepatoma cells results in elevated p53 levels accumulating predominantly in the nucleus or in both the nucleus and cytoplasm (Figure 2a ). FLAG-NS5A is localized to the perinuclear region of the cytoplasm in the NS5A permanently transfected Hep3B cells ( Figure 2b ). As shown in Figure 2c , NS5A colocalizes with the p53 in the perinucleoplasmic region of Hep3B cells coexpressing p53 and Flag-NS5A proteins. In contrast, p53 does not associate with FLAG in cells coexpressing p53 and FLAG proteins (Figure 2d ). p53 transcriptional activity is downregulated in a stable HCV NS5A-transfected hepatoma cell line
To investigate whether the association of HCV NS5A protein and p53 can influence transcription activation by p53, we assayed the effect of NS5A on the activity of a reporter gene containing 15 repeats of the binding sites for p53 by transient transfection. p53-Luc was cotransfected with vector or p53-expressing plasmid into p53-null Hep3B cells permanently transfected with FLAG or FLAG-NS5A. Forty-eight hours after transfection, the cells were assayed for luciferase activity. As shown in Figure 3a , the relative firefly luciferase activity of p53-Luc/FLAG transfected cell lysates in the presence of p53 was 14.6+1.9 (mean+s.d.) times higher than that in the absence of p53 (Figure 3a) . In contrast, the relative firefly luciferase activity of p53-Luc/FLAG-NS5A-permanent cell lysates only increased to 4.1+2.6 folds after adding p53, suggesting that NS5A may suppress p53-mediated transcription activation (Figure 3a) .
HCV NS5A suppresses the transcriptional transactivation activity of p53 in a dose-dependent manner To further determine whether the inhibition of p53-mediated transcription activation by NS5A occurred in a dose-dependent manner, p53-Luc was co-transfected with a fixed level of p53 and various amounts of pCXN2-NS5A into Hep3B cells. Forty-eight hours after transfection, the cells were assayed for luciferase activity. Luciferase activities are expressed by taking the activity of lysate from pMT-p53-transfected cells in the absence of NS5A as 1. NS5A protein suppressed luciferase activity from p53 response element-directed transactivation in a dose-dependent manner in the presence of exogenous p53 (Figure 3b ).
To further dissect the mechanism of the inhibitory effect of NS5A on a transcriptional transactivation by p53, COS7 cells were co-transfected with pM-p53, a mammalian expression vector for generating Gal4 DNA binding domain and p53 fused protein and pG5CAT reporter plasmid (Clontech), a chloramphenicol acetyltransferase (CAT) reporter plasmid possessing five GAL4-binding sites and an adenovirus E1b minimum promoter. Cells were harvested 48 h after transfection and CAT assays were performed. CAT activities are expressed by taking the activity of lysate from pM-p53-transfected cells in the absence of NS5A as 1. As shown in Figure 3c , NS5A protein inhibited the activation by Gal-p53 in a dosedependent fashion, suggesting that the inhibition effect of NS5A on the transcriptional transactivation by p53 may not be through the influence of NS5A on DNA affinity of p53 and its targeting gene. Colocalization of HCV NS5A and p53 in Hep3B cells by immunofluorescent staining. FLAG-and FLAG-NS5A permanently transfected Hep3B cells plated in four-chambered coverglass were transfected with 1 mg of p53. Forty-eight hours after transfection, the cells were fixed and permeabilized, after which they were then double-stained with a monoclonal antibody to FLAG (1 : 100) and a polyclonal antibody to p53 (1 : 100). After washing, the cells were simultaneously immunostained for p53 (FITC) and FLAG-NS5A (R-phycoerythrin) as described in Materials and methods. (c) Yellow regions reflected areas of colocalization of p53 and FLAG-NS5A in a stable FLAG-NS5A Hep3B cell line cotransfected with p53. (d) As a control, p53 does not associate with FLAG in a stable FLAG Hep3B cell line cotransfected with p53. Confocal microscopy was performed using an Olympus confocal microscope p53-dependent effect on NS5A on the p21/waf1 expression Based on co-expression of p53 binding site/luciferase reporter construct and p53-expressing plasmid in NS5A-expressing stable cell line Hep3B (p537/7), we suggested that NS5A inhibits transcriptional activity of p53 target genes. To further elucidate the result, we analysed the p21/waf1, one of p53 targeting genes, expression in FLAG-and FLAG-NS5A stable cell line Hep3B (p537/7). FLAG-and FLAG-NS5A-expressing stable cell line Hep3B (p537/7) were transfected with p53-expressing plasmid (pCXN2-p53) or vector (pCXN2). After 48 h of transfection, cell lysates were prepared and an equal amount of proteins was analysed for p21/waf1 expression. As shown in Figure 4a , the levels of endogenous p21/waf1 expression was almost undetectable in the absence of p53 transfection. Furthermore, p21/waf1 expression was down-regulated in FLAG-NS5A stable Hep3B cells as compared to that of FLAG stable Hep3B cells in the presence of p53. To examine whether this decrease in p21/waf1 expression was due to a change in the amount of p53, the expression of p53 was measured by immunoblotting. The result showed the p53 expression level remained similar in both FLAG-and FLAG-NS5A stable cell lines when an equal amount of pCXN2-p53 plasmid was transfected ( Figure 4b ). atubulin expression was shown to confirm that an equal amount of protein was loaded for immunoblotting ( Figure 4c ). These results indicate that the decreased expression level of the p21/waf1 was not due to a decrease in p53 protein level and NS5A-mediated transcriptional repression of p21/waf1 appears to be p53-dependent. Figure 3 The NS5A protein inhibits transcriptional control by p53. (a) The p53-Luc reporter plasmid was cotransfected with either the control pMT expression vector or the p53-expressing plasmid pMT-p53 (0.3 mg pMT-p53) into stable Hep3B cells transfected by pCXN2-FLAG or pCXN2-FLAG-NS5A. The total amount of plasmid DNA (1 mg) was kept constant through the addition of an empty vector (pMT) in each transfection. Cell extracts were prepared 48 h post-transfection and luciferase activity was determined. All the results were normalized against the control (i.e., stable FLAG-expressing Hep3B cells cotransfected with pMT, pRL-tk and p53-Luc) to generate the relative luciferase activities. (b) Studies conducted in Hep3B cells. The indicated amounts of effector plasmid (pCXN2-NS5A) were cotransfected with 0.19 mg p53-Luc as the reporter plasmid. The total amount of plasmid DNA (1 mg) was kept constant through the addition of an empty vector (pCXN2) in each transfection. Cell extracts were prepared 48 h post-transfection and luciferase activity was determined. All the results were normalized against the control (i.e., Hep3B cells cotransfected with pMT-p53, pRL-tk and p53-Luc) to generate the relative luciferase activities. (c) CAT assays in COS7 cells, showing NS5A blocks activation of a reporter (pG5CAT) by a Gal4 fusion protein containing p53 (pM-p53) in a dose-dependent fashion. All the results represent the average of at least three different experiments Figure 4 Decreased induction of endogenous p21 protein by HCV NS5A protein. FLAG-and FLAG-NS5A-stable Hep3B cells were transfected transiently with an equal amount of pCXN2-p53 or pCXN2. Forty-eight hours later, cells were harvested and the protein concentration was normalized and then used for immunoblotting of (a) p21, (b) p53, and (c) a-tubulin protein with corresponding antibodies, respectively. Representative results of the immunoblotting are indicated HCV NS5A abrogates p53-mediated apoptosis in Hep3B hepatoma cells
To evaluate the impact of NS5A expression upon p53-induced apoptosis, two permanently transfected Hep3B cell lines (FLAG, and FLAG-NS5A) were transfected with a p53 expression plasmid (pCXN2-P53). In the absence of p53, no difference in the percentage of apoptotic cells, 1.2+0.5 and 0.5+0.2%, was found in the Hep3B-FLAG and Hep3B-FLAG-NS5A cells, respectively. However, in the presence of p53, the Hep3B-FLAG-NS5A cells contained 0.6+0.2% apoptotic cells, while Hep3B-FLAG cells contained 11.4+2.1% apoptotic cells (Figure 5a ). There was an overexpression of p53-induced apoptosis in FLAG stable transfectant, but not in FLAG-NS5A stable transfectants (Figure 5a ).
To further elucidate whether the suppression of p53-mediated apoptosis in stable NS5A-expressing Hep3B cells is due to the interaction of p53 and NS5A, apoptosis of Hep3B cells co-transfected with p53 and NS5A (full length) or its deletion mutants (N-terminal or C-terminal) were analysed. Consistent with the finding in permanently transfected cell lines, Hep3B cells transiently co-transfected with p53 and vector control or N-terminal of NS5A, which did not bind to p53, showed a sub-G 0 peak, characteristic of apoptosis (percentage of apoptotic cells is 13.8+3.5 and 11.4+2.7%, respectively) ( Figure 5b ). In contrast, full length of NS5A and its C-terminal mutant, both of which interacted with p53, showed reduced sub-G 0 peak after PI staining (percentage of apoptotic cells is 1.9+1.1 and 2.0+1.4%, respectively), suggesting HCV NS5A inhibited p53-mediated apoptosis through interaction of NS5A and p53 in transiently transfected Hep3B cells (Figure 5b ).
Interaction between HCV NS5A and hTAF II 32
Since HCV NS5A has a FXXjj motif (F, phenylalanine, X, any amino acid; j, hydrophobic amino acids), which is a general recognition element of acidic activation domains for hTAF II 32, at aa 2147 and aa 2281 to 2285 of the prototype HCV type 1b, HCV-J (Kato et al., 1990) (Figure 6a ), it is possible that HCV NS5A may interact with hTAF II 32. The ability of NS5A to interact with hTAF II 32 was examined using an in vivo co-immunoprecipitation assay. COS-7 cells were transfected with FLAG-NS5A expression plasmid and with hTAF II 32 expression plasmid. Cell lysates, obtained 48 h after transfection, were immunoprecipitated by FLAG M2 antibody resin, and then immunoblotted by anti-hTAF II 32 antibody. hTAF II 32 was co-immunoprecipitated with FLAG-NS5A but not FLAG vector (Figure 6b ). To further map the interaction region of hTAF II 32 on NS5A, two HCV NS5A deletion mutants expression plasmids, pCXN2-FLAG-NS5A-N (aa 2135 to 2419 of HCV) and pCXN2-FLAG-NS5A-C (aa 1973 to 2331) were included for co-immunoprecipitation assay. Full-length NS5A N-terminal 162 amino acids-deleted NS5A bound to hTAF II 32, whereas C-terminal 88 amino acids-deleted NS5A did not bind to hTAF II 32 ( Figure  6c ). These results suggest that the C-terminus of NS5A (aa 2331 to 2419) may be important for interaction with hTAF II 32.
Subcellular localization of HCV NS5A and hTAF II 32 protein
To further demonstrate that HCV NS5A protein interacts with hTAF II 32 in vivo, immunofluorescence staining of NS5A and endogenous hTAF II 32 in FLAG-NS5A-or FLAG-stable Hep3B cells was performed. The localization of HCV NS5A protein was determined by green fluorescence, whereas the localization of hTAF II 32 was determined by red fluorescence. Consistent with the data shown in Figure  2 , NS5A is localized in the cytoplasm of NS5A permanently transfected Hep3B cells (Figure 7a; upper panel, left) . Endogenous hTAF II 32 is localized predominantly in the nucleus of FLAG Hep3B cells To further confirm the results from immunofluorescence staining that HCV NS5A sequesters hTAF II 32 in cytoplasm, the localization of hTAF II 32 and its interaction with NS5A were determined from subcellular fractions of FLAG-NS5A-or FLAG-stable Hep3B cells transfected with HA-hTAF II 32. As shown in Figure 7b , most of HA-hTAF II 32 appeared in cytosolic fraction in the presence of NS5A whereas it localized in both nuclear and cytosolic fractions in the absence of NS5A. In addition, FLAG-NS5A immunoprecipitates HA-hTAF II 32 exclusively in the cytoplasmic fraction of FLAG-NS5A stably transfected Hep3B cells. These results suggest that hTAF II 32 may interact with and be sequestered by HCV NS5A in the cytoplasm of Hep3B cells.
Discussion
HCV is well recognized as a major causative agent of hepatocellular carcinoma throughout the world (Kuo Figure 6 The C-terminus of HCV NS5A interacts with hTA-F II 32 (a) FXXjj motif, which is a general recognition element of acidic activation domains for hTAF II 32. F, phenylalanine; X, any amino acid; j, hydrophobic amino acids. Numbers represent the amino acid residues in the prototype HCV type 1b, HCV-J (Kato et al., 1990) . (b) COS-7 cells were transfected with pCXN2-FLAG-NS5A or pCXN2-FLAG vector and pCXN2-HA-hTAF II 32. Cell lysates were immunoprecipitated with anti-FLAG antibody resin, and then analysed by immunoblotting using anti-HA antibody. An arrow shows the coprecipitated HA-hTAFII32. *represents the location of light chain of antibody. (c) Interactions of FLAG-NS5A, FLAG-NS5A-N, or FLAG-NS5A-C with HA-hTAF II 32 were examined by immunoprecipitation using anti-FLAG antibody resin followed by Western blot analysis using anti-HA monoclonal antibody Saito et al., 1990; Shiratori et al., 1995) . Hepatocellular carcinoma accounts for over 90% of primary liver cancers and may progress through inactivation of the p53 gene (Hsu et al., 1991) . Low correlation between p53 gene abnormalities and the HCV-associated HCCs suggest that p53 mutations may not play a significant role in HCV-associated hepatocarcinogenesis (Shieh et al., 1993) . The interactions of viral proteins of HCV with tumor suppressor p53 to inactivate p53 might play a critical role in the oncogenesis of HCV. In this study, we showed that HCV NS5A interacted with p53 and hTAF II 32. Complementing our in vivo binding data are the confocal microscopy results, indicating that NS5A colocalizes with p53 in the cytoplasmic region of hepatoma cells. In addition, this interaction of NS5A and p53 inhibits the transcriptional transactivation by p53 and hTAF II 32. These interactions are essential for abrogating p53-mediated apoptosis. Viral proteins may influence cellular genes, which in turn may be involved in the negative regulation of tumor suppressor genes. Inactivation of cellular genes may be a mechanism for the disruption of normal cell growth (Thompson, 1995) . Because p53 maintains the genetic integrity of cells by controlling progression through the cell cycle, the loss of p53 function, therefore, appears to be associated with increased genetic instability and the accumulation of mutations, which is likely to precede oncogenic transformation (Levine, 1993) . Various tumor viruses encode proteins that interact with p53, including T antigen from SV40 (Lane and Crawford, 1979) , E6 from human papillomavirus (Dyson et al., 1989) , E1B 55-kDa from adenovirus (Sarnow et al., 1982) , HBx from HBV (Wang et al., 1994 (Wang et al., , 1995 Ueda et al., 1995) , and core protein from HCV (Otsuka et al., 2000; Ray et al., 1997; Lu et al., 1999) . Most of the p53-interacting viral proteins were reported to suppress p53 function (Scheffner et al., 1992; Wang et al., 1994 Wang et al., , 1995 Dobner et al., 1996; Muralidhar et al., 1996; Uchida et al., 1996; Elmore et al., 1997; Mulloy et al., 1998; Pise-Masison et al., 1998; Prost et al., 1998; Ray et al., 1997; Sheppard et al., 1999) . If the p53 protection pathway is inactivated, the development of chromosomal abnormalities or mutations during the chronic viral infection is increased.
One mechanism of p53 inactivation is the retention of the protein in the cytoplasm, which prevents its binding to DNA and transactivating the appropriate target genes. The adenovirus E1B 55-kDa protein binds to p53 and prevents the nuclear localization of p53 (Zantema et al., 1985a,b) . p53 exclusion from the nucleus has also been described in hepatitis B virus X gene-expressing cells (Ueda et al., 1995; Elmore et al., 1997; Takada et al., 1997) . Our results suggest that the HCV NS5A binds to and colocalizes p53 in perinucleoplasmic region of cytoplasm. Since higher levels of nuclear p53 seems to be favored to induce apoptosis , partial cytoplasmic sequestration of p53 by HCV NS5A may sufficiently reduce the concentration of nuclear p53, resulting in suppression of apoptosis. The function of NS5A protein on the hepatocarcinogenesis may not be correlated with the mutation of p53 protein, but may be correlated with the retention of normal p53 protein in the cytoplasm instead of the nucleus, resulting in genetic instability in the hepatocyte. In addition to cytoplasmic sequestration, HCV NS5A may abrogate p53-mediated apoptosis by influencing the transcriptional transactivation activity of p53.
Since the N-terminal 27 aa of NS5A causes retention of a nuclear protein in the cytoplasm, Nterminus-deleted NS5A was found to be localized in the nucleus, while full-length NS5A was localized in the cytoplasm (Satoh et al., 2000) . Therefore, it is possible that only N-terminus-deleted NS5A could be localized in the nucleus, and thus function as a transcriptional activator. One previous report showed a small amount of NS5A protein staining in the nucleus in a hepatoma cell line transfected with subgenomic HCV type 1b RNA (Lohmann et al., 1999) . Furthermore, NS5A was cleaved by a caspaselike protease(s), in which one of the cleaved products was localized in the nucleus (Satoh et al., 2000) . One possibility for abrogation of the transcriptional transactivation of p53 by N5A may result from a competitive inhibition at the level of transcription factors. We and other groups have showed that the Nterminus-deleted NS5A functions as a transcriptional activator in both yeast and mammalian cells (Chung et al., 1997; Kato et al., 1997; Tanimoto et al., 1997; Fukuma et al., 1998) . Several viral activators regulate the transcription of cellular or viral genes through interaction with various components of the basal transcriptional machinery. A variety of in vitro binding assays have indicated that the acidic activation domain of VP16, a herpes virus protein, binds to various components of pre-initiation complexes, such as TBP and hTAF II 32 (Stringer et al., 1990; Ingles et al., 1991; Uesugi et al., 1997) . NS5A has a FXXjj (F, phenylalanine; X, any amino acid; j, hydrophobic amino acids) motif, which is a general recognition element of acidic activation domains for hTAF II 32 (Uesugi et al., 1997) , at aa 2147 to 2151 and aa 2281 to 2285 of HCV-J (Kato et al., 1990) , respectively. It is intriguing to speculate that NS5A may interact with the host's general transcriptional factors, such as hTAF II 32, because of its acidic nature (Kato et al., 1997) . As we have shown, that HCV NS5A indeed binds to and colocalizes hTAF II 32 in the cytoplasm. Since the transcriptional activation of p53 is mediated by hTAF II 32 (Lu and Levine, 1995; Thut et al., 1995) , it is possible that NS5A suppresses transcriptional activation of p53 through its interaction with hTAF II 32.
The mechanism by which HCV NS5A inactivates p53 activity is unclear. It is likely to mimic the mechanisms used by the simian virus 40 large T antigen and adenovirus E1B 55-kDa proteins since these viral proteins both bind and inhibit p53-mediated apoptosis (Neil et al., 1997) . p53-mediated apoptosis is an important factor in maintaining tissue homeostasis and preventing neoplastic transformation (Lowe et al., 1993a,b; Symonds et al., 1994) . Inactivation of p53-mediated apoptosis by HCV NS5A could lead to the disruption of the normal cellular surveillance mechanism for removing damaged hepatic cells, which could result in the accumulation of genetically abnormal cells. Since the activation of p53 can lead to apoptosis , this interaction of NS5A and p53 may represent a viral mechanism to persist viral infection by preventing HCV infected cells from apoptosis. In fact, introduction of NS5A into murine fibroblasts (NIH3T3) promoted anchorageindependent growth and tumor formation in nude mice, supporting the oncogenic and anti-apoptotic nature of NS5A Ghosh et al., 1999) . In this report, we demonstrate that the full length and N terminal deletion mutant bind to p53. These interactions correlate with the relative resistance of p53-mediated apoptosis. It is likely that the interaction of NS5A and p53 may contribute to the potential properties of NS5A. Thus, functional inactivation of p53 by HCV NS5A could play an important role in the development of hepatocellular carcinoma.
Consistent with our results using NS5A from HCV genotype 1b, Majumder et al. (2001) showed that NS5A from HCV genotype 1a also physically associates with p53 and down-regulates p21/waf1 gene expression in a p53 dependent manner just before our submission. By using the mammalian two-hybrid system, they showed that the p53-interacting domain of NS5A is located within the first 150 amino acid residues. However our in vivo coimmunoprecipitation suggests that the p53-interacting domain is located in the C-terminal 285 amino acids of NS5A (Figure 1b) . In addition, they did not show the biological significance of the interaction of NS5A and p53. We clearly conclude that the interaction of NS5A and p53 correlates well with the inhibition effect of HCV NS5A on p53-mediated apoptosis. Furthermore, we suggest that the interaction of HCV NS5A and human TAF II 32 may be involved in the suppression of NS5A on the transcriptional activation from p53.
In conclusion, the present study showed that full length and C-terminus of HCV NS5A interact with p53, and these interactions correlate with the abrogation of p53-mediated apoptosis in Hep3B cells. In addition, HCV NS5A complexes with p53 and hTAF II 32 in the cytoplasm by confocal microscopy, partially preventing their nuclear entry and their ability to induce transcriptional transactivation. Our results suggest that HCV NS5A influences the various functions of p53 in NS5A-transfected cells and may play an important role in viral persistent infection, and in the pathogenesis of HCV-associated hepatocellular carcinoma.
Materials and methods
Plasmids
HCV RNA was extracted from the serum of a 50-year-old male patient with chronic hepatitis C type 1b using SepaGene-RV (Sankyo Junyaku, Tokyo, Japan). Synthetic oligonucleotides and PCR were used to engineer initiation and termination codons as well as specific epitope tags for HCV NS5A expression construction. Type 1b HCV NS5A region was amplified by PCR with NS5A-specific primers using pM-NS5A/F5-R5 (encoding NS5A) (Kato et al., 1997) as a template. All synthetic primers had a XhoI restriction site for subcloning PCR products. Amplified products were digested with XhoI and then cloned into the XhoI site of pCXN2 (kindly provided by J Miyazaki, Osaka University, Japan), a mammalian expression vector having a b-actinbased CAG promoter (Niwa et al., 1991) , to generate various pCXN2-NS5A constructs.
N-terminal FLAG epitope (FLAG: DYKDDDDK)-tagged full-length NS5A protein expression plasmid (pCXN2-FLAG-NS5A-F) was constructed by subcloning the XhoI fragment of pCXN2-NS5A into the XhoI site of pCXN2-FLAG vector. pCXN2-FLAG-NS5A-N and pCXN2-FLAG-NS5A-C, which express FLAG-tagged Cterminal 88 aa deleted NS5A (359 aa, aa 1973 to 2331) and N-terminal 162 aa deleted NS5A (285 aa, aa 2135 to 2419), were also obtained by inserting the PCR products ( Figure  1a) .
The pCXN2-p53, a human wild type p53 expression vector was constructed by subcloning the p53 cDNA fragment with a XhoI site into pCXN2, which was amplified by PCR using AdCAp53, a human wild type p53 expression adenovirus described previously (Ohashi et al., 1999) as a template. To generate pM-p53, p53 cDNA was subcloned into EcoRI and PstI sites of the pM vector (Clontech Laboratories, Palo Alto, CA, USA), a mammalian expression vector for generating Gal4 DNA binding domain fusion protein.
hTAF II 32 cDNA was a gift from Dr R Tjian (University of California, CA, USA) and hTAF II 32 expression plasmid (pCXN2-hTAF II 32) was generated by subcloning hTAF II 32 cDNA into pCXN2 vector. Nterminal hemagglutinin (HA: YPYDVPDYA)-tagged hTAF II 32 expression plasmid (pCAGGS-HA-hTAF II 32) was generated by subcloning hTAF II 32 cDNA into pCAGGS-HA vector. All cloned plasmids were purified using Endofree plasmid kit (Qiagen, Hilden, Germany). Nucleotide sequencing of constructed plasmids was performed using an autosequencer (PE Applied Biosystems, Foster City, CA, USA) and the dye-termination method to confirm gene integration. Expression of cloned genes was confirmed by immunoblotting the cell extracts of COS-7 cells transfected with each plasmid using corresponding antibody.
Cell lines
The SV40-transformed African green monkey cell line, COS-7, was obtained from the Riken Cell Bank (Tsukuba, Japan). COS-7 cells were maintained in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA) and 2 mM Lglutamine at 378C in a 5% CO 2 atmosphere. Hep3B cells, p53-negative human hepatoma cells obtained from American Type Culture Collection (Rockville, MD, USA), were grown in D-MEM with 10% FBS, 1 mM sodium pyruvate, and 1% non-essential amino acids. For selection of FLAG-NS5A or FLAG stable transfectants, Hep3B cells were transfected with pCXN2-FLAG-NS5A or pCXN2-FLAG plasmid and selected by resistance to G418 (Gibco-BRL) at the concentration of 400 mg/ml. The protein expression was confirmed by Western blots.
Immunoprecipitation and immunoblotting
To test the ability of the HCV NS5A protein to interact with p53 and to map the site of the possible interaction on p53, we performed co-immunoprecipitation and protein blot experiments. Approximately 4610 5 COS-7 cells were plated onto the wells of a 6-well tissue culture plate (Iwaki Glass, Chiba, Japan) 24 h before transfection. The pCXN2-FLAG vector or NS5A expressing plasmids (pCXN2-FLAG-NS5A, pCXN2-FLAG-NS5A-N, pCXN2-FLAG-NS5A-C) were transiently cotransfected with p53 expressing plasmid (pCXN2-p53) into COS-7 cells using the FuGene 6 transfection reagent (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. Unless otherwise specified, the same amount of DNA (0.5 mg) was used for each expression plasmid in each cotransfection experiment.
To rule out the possibility that NS5A interacts with p53 through SV40 large T antigen which is constitutively expressed in COS-7 cells, Hep3B cells plated in a 60 mm culture plate were transfected with 1 mg of pCXN2-p53 and pCXN2-FLAG vector or pCXN2-FLAG-NS5A plasmids, respectively. Forty-eight hours after the transfection, coimmunoprecipitation experiments were performed to detect the interaction of NS5A and p53 in Hep3B cells.
To map the region of NS5A that interacts with hTAF II 32, the pCXN2-FLAG vector or NS5A expressing plasmids (pCXN2-FLAG-NS5A, pCXN2-FLAG-NS5A-N, pCXN2-FLAG-NS5A-C) were transiently cotransfected with hTAF II 32 expressing plasmid (pCXN2-hTAF II 32) into COS-7 cells using the same method described above.
For co-immunoprecipitation experiments, the cells were harvested 48 h after transfection. Cell lysates were prepared in an IP buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 0.25% gelatin, 0.02% sodium azide, 100 mg/ml phenylmethylsulfonyl fluoride, and 1 mg/ml aprotinin. To map the interaction regions between NS5A and p53 or hTAF II 32, cell lysates were immunoprecipitated by incubation with FLAG M2 antibody resin (Eastman Kodak, New Haven, CT, USA) for 4 h at 48C. After being washed four times with the IP buffer, immunoprecipitates were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting with the corresponding antibodies: antip53 antibody (Santa Cruz Biotechnology, CA, USA) to detect p53, anti-hTAF II 32 antibody (Santa Cruz Biotechnology, CA, USA) to detect hTAF II 32 and anti-HA antibody (Santa Cruz Biotechnology, CA, USA) to detect HA-hTAF II 32. Immunoblotting was performed using the ECL-plus Western blotting detection system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
To determine the effects of HCV NS5A on expression levels of p21, endogenous levels of p21 protein were determined by Western blot analysis using FLAG-and FLAG-NS5A-expressing stable Hep3B cells (p537/7) transiently transfected with p53-expressing plasmid (pCXN2-p53) or vector (pCXN2). After 48 h of transfection, cell extracts were adjusted to the same protein concentration by Protein assay kit (Bio-Rad). Equal amount of protein was analysed by SDS -PAGE and Western blotting with anti-p21 goat polyclonal antibody (Santa Cruz Biotechnology, CA, USA). The same membrane was treated with 2 M glycine (pH 2.8) for 30 min and reprobed with anti-p53 polyclonal antibody and anti-a tubulin antibody (Santa Cruz Biotechnology, CA, USA), respectively.
In vitro binding assay
A glutathione S-transferase (GST)-NS5A fusion protein or GST was expressed in E. coli strain BL21 (DE3). Expression of GST fusion proteins was induced by adding 0.2 mM isopropyl-1-thio-b-D-galactopyranoside for 2 h at 308C. Bacteria were harvested, washed with phosphate-buffered saline (PBS), resuspended in lysis buffer (1% Triton X-100 in PBS), and sonicated on ice, GST-NS5A fusion proteins were purified from bacterial lysates with glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech).
35 S-methioninelabeled p53 protein was generated by using a coupled in vitro transcription and translation system (Promega) with pBluescript-p53 as a template. Approximately equal amounts of GST and GST-NS5A fusion proteins, as judged by Coomassie Blue staining, were bound to glutathione-Sepharose and incubated with 35 S-methionine-labeled p53 protein in binding buffer (40 mM HEPES, pH 7.4, 100 mM KCl, 100 mM ZnCl 2 , 0.1% Nonidet P-40, 20 mM b-mercaptoethanol, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF) at 48C overnight. Beads were washed four times with the binding buffer, and bound proteins were separated by electrophoresis on a 10% SDS -PAGE and visualized by autoradiography.
Confocal immunofluorescence
FLAG or FLAG-NS5A stably-transfected Hep3B cells plated in a four-well chambered coverglass (Nunc, Inc. Naperville, IL, USA) were transfected with 1 mg of p53. Forty-eight hours after transfection, the cells were fixed in 4% paraformaldehyde and permeabilized in 0.2% Triton X100. The cells were then double-stained with a rabbit polyclonal antibody to p53 (1 : 100) (Santa Cruz; FL-393) followed by FITC-conjugated anti-rabbit IgG antibody (1 : 250 dilution; DAKO), and a monoclonal antibody to FLAG (1 : 100) (Sigma) followed by RPE-conjugated anti-mouse IgG antibody (1 : 250 dilution; DAKO). Confocal microscopy was performed using an Olympus IX 70 FLUOVIEW confocal microscope. FLAG or FLAG-NS5A stably-transfected Hep3B cells plated in a four-well chambered coverglass were fixed in 4% paraformaldehyde and permeabilized in 0.5% Triton X100. The cells were then double-stained with a goat polyclonal antibody to hTAF II 32 (1 : 100) (Santa Cruz; C19) followed by TRITC-conjugated anti-goat IgG antibody (1 : 100 dilution; Jackson), and a monoclonal antibody to FLAG (1 : 100) (FLAG-M2; Sigma) followed by FITC-conjugated antimouse IgG antibody (1 : 100 dilution; Jackson). Confocal microscopy was performed to detect the localizations of HCV NS5A and endogenous hTAF II 32.
Transient transfection and luciferase assay
Approximately 4610 5 stable FLAG or FLAG-NS5A-expressing Hep3B cells were plated onto a 6-well tissue culture plate (Iwaki Glass, Chiba, Japan) 24 h before transfection. Transfection was performed using FuGene6 Transfection Reagent (Boehringer Mannheim) according to the manufacturer's instructions. p53-Luc (Stratagene, La Jolla, CA, USA), a vector containing the Photinus pyralis (firefly) luciferase reporter gene driven by a basic promoter element (TATA box) plus an inducible cis-enhancer element containing 15 repeats of the p53 binding sequences (TGCCTGGACTTGCCTGG), was used as a reporter plasmid. To check transfection efficiency, pRL-tk, a control plasmid to express Renilla reniformis (seapansy) luciferase driven by herpes simplex virus thymidine kinase (Tokyo Inc, Tokyo, Japan), was used. pMT-p53, a p53-expressing plasmid under the control of metallothione promoter, was used for p53 expression. Unless otherwise specified, the transfection complexes containing a total of 1 mg of plasmids (0.19 mg of p53-Luc, 0.01 mg of pRL-TK, 0-0.1 mg of pMT-p53, 0.7-0.8 mg of pMT vector adjusted to a total of 1 mg) were added to each well of the 6-well plate. Cells were harvested 48 h after transfection and luciferase assays were carried out with the Dual-luciferase reporter assay system according to the manufacturer's protocol (Promega). Firefly-luciferase activity and seapansy-luciferase activity were measured as relative light unit (RLU) with a luminometer (Lumat LB9507, EG&G Berthold, Bad Wildbad, Germany). Firefly-luciferase activity was normalized for transfection efficiency based on seapansyluciferase activity. All assays were performed at least in triplicate.
To determine whether the inhibition of p53-mediated transcription activation by NS5A occurred in a dosedependent manner, p53-Luc was co-transfected with a fixed level of pMT-p53 (0.3 mg) and various amounts of pCXN2-NS5A (0.2 -0.7 mg) or pCXN2 vector into Hep3B cells. Cells were harvested 48 h after transfection and luciferase assays were carried out with the Dual-luciferase reporter assay system as described above. All assays were performed at least in triplicate.
Transient transfection and CAT assay
Approximately 10 6 COS7 cells were plated onto a 6-cmdiameter tissue culture plate (Iwaki Glass) 24 h before transfection. Transfection was performed using FuGene6 Transfection Reagent (Boehringer Mannheim) according to the manufacturer's instructions. The efficiency of transfection was checked by cotransfection of the b-galactosidase expression plasmid with pM-P53 and pG5CAT reporter plasmid (Clontech), a chloramphenicol acetyltransferase (CAT) reporter plasmid possessing five GAL4-binding sites and an adenovirus E1b minimum promoter. Unless otherwise specified, the transfection complexes containing a total of 2 mg of plasmids (0.5 mg of pG5CAT, 0.5 mg of pb-gal, 0.5 mg of pM-p53, 0-0.5 mg of pCXN2-NS5A, 0-0.5 mg of pCXN2 vector adjusted to a total of 2 mg) were added to each plate. Cells were harvested 48 h after transfection and CAT assays were carried out as described previously (Kato et al., 1997) . All assays were performed in triplicate.
Analysis of DNA fragmentation by flow cytometry
For detection and quantification of apoptosis, nuclear staining with propidium iodide in concert with flow cytometric analysis was used. Forty-eight hours after transfection with p53-expressing plasmid into stable FLAGor FLAG-NS5A-expressing Hep3B cells, the cells were fixed in cold 100% ethanol for 1 h, and stained with PBS solution containing RNase A (100 mg/ml) and propidium iodide (25 mg/ml) (Sigma) at room temperature for 1 h in the dark. Subsequently, the nuclei were subjected to DNA fragmentation analysis in a FACScalibur (Becton Dickinson, San Jose, CA, USA). Based on propidium iodide staining, nuclei in the sub-G 0 marker window were considered to represent apoptotic cells.
To further elucidate whether the suppression of p53-mediated apoptosis in NS5A stably transfected Hep3B cells is through the interaction between p53 and NS5A, Hep3B cells plating in 10 cm-diameter dishes were co-transfected with p53 and NS5A or its deletion mutants (N-terminal or C-terminal of NS5A). Forty-eight hours after transfection, cells were harvested and treated as mentioned above the DNA fragmentation analysis in a FACScalibur.
Subcellular fractions
FLAG or FLAG-NS5A stably-transfected Hep3B cells plated in a six-well culture plate were transfected with 1 mg of pCAGGS-HA-hTAF II 32. Forty-eight hours after transfection, the cells were trypsinized and collected. After washing with PBS, cells were resuspended in buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM PMSF, 0.5 mM DTT) for 5 min on ice. Cells were centrifuged at 10 000 r.p.m. for 2 min and the supernatant was collected as cytosolic fraction. The pellet was washed with 700 ml of buffer A and spun at 10 000 r.p.m. for 5 min. The pellet was resuspended homogenously in buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 0.2 mM EDTA, 1.5 mM MgCl 2 , 0.5 mM PMSF, 0.5 mM DTT) and rotated at 48C for 30 min. Nuclear extract was collected after centrifugation at 14 000 r.p.m. for 10 min. The protein concentrations were measured with Protein Assay (Bio-Rad) and 500 mg lysates were incubated with FLAG M2 resin overnight. Fifty microgram lysates and immunoprecipitates were solubilized with SDS -PAGE sample buffer and subjected to 12.5% SDS -PAGE and Western blot analysis with anti-HA polyclonal antibody (Santa Cruz Biotechnology, CA, USA).
